Icahn Says Affiliates Voluntarily Dismiss Suit Against Amylin (AMLN)
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Carl C. Icahn today announced that his affiliates had voluntarily dismissed their lawsuit against Amylin Pharmaceuticals (Nasdaq: AMLN) which had sought an extension of the deadline to nominate directors at the 2012 annual meeting of shareholders. Mr. Icahn released the following statement:
The decision to discontinue our lawsuit seeking to extend the director nomination deadline was the result of discussions I had with Daniel Bradbury, Amylin’s chief executive officer, that we agreed would not be publicly disclosed.
Mr. Icahn reiterated that he continues to strongly believe that the company should be sold at this time.
The decision to discontinue our lawsuit seeking to extend the director nomination deadline was the result of discussions I had with Daniel Bradbury, Amylin’s chief executive officer, that we agreed would not be publicly disclosed.
Mr. Icahn reiterated that he continues to strongly believe that the company should be sold at this time.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin presents new REDUCE-IT data at ESC Congress 2026
- Activist hedge fund Engine Capital has built a 1.5% stake in EPAM Systems - Reuters
- Wendy's stock plunges as Trian shelves take-private bid, Reuters reports
Create E-mail Alert Related Categories
Hedge Funds, LitigationRelated Entities
Carl IcahnSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
